Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MORECell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
| CAR-M0158-YC | Anti-GPC3 (CBYCD-474) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | CBYCD-474 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-M0569-YC | Anti-GPC3 (CBYCD-474) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYCD-474 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6759 | Anti-GPC3 (CBFYH-0436) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0436 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6766 | Anti-GPC3 (CBFYH-0435) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0435 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6802 | Anti-GPC3 (CBFYH-2978) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2978 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6803 | Anti-GPC3 (CBFYH-2979) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2979 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6804 | Anti-GPC3 (CBFYH-2980) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2980 | Rabbit | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY6805 | Anti-GPC3 (CBFYH-0434) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0434 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7557 | Anti-GPC3 (CBFYH-0436) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0436 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7564 | Anti-GPC3 (CBFYH-0435) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0435 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7600 | Anti-GPC3 (CBFYH-2978) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2978 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7601 | Anti-GPC3 (CBFYH-2979) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2979 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7602 | Anti-GPC3 (CBFYH-2980) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-2980 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-WFY7603 | Anti-GPC3 (CBFYH-0434) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBFYH-0434 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2988 | Anti-GPC3 (2G9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2G9 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2989 | Anti-GPC3 (2G9) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2G9 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2990 | Anti-GPC3 (4G5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 4G5 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2991 | Anti-GPC3 (4G5) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 4G5 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2992 | Anti-GPC3 (3D8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3D8 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2993 | Anti-GPC3 (3D8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3D8 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2994 | Anti-GPC3 (2E10) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2E10 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2995 | Anti-GPC3 (2E10) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2E10 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2996 | Anti-GPC3 (huG5S1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | huG5S1 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2997 | Anti-GPC3 (huG5S1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | huG5S1 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2998 | Anti-GPC3 (Codrituzumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Codrituzumab | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP2999 | Anti-GPC3 (Codrituzumab) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Codrituzumab | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3000 | Anti-GPC3 (HN3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HN3 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3001 | Anti-GPC3 (HN3) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | HN3 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3002 | Anti-GPC3 (hGES1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hGES1 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3003 | Anti-GPC3 (hGES1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | hGES1 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3004 | Anti-GPC3 (15G1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 15G1 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3005 | Anti-GPC3 (15G1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 15G1 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3006 | Anti-GPC3 (M18D4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | M18D4 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3007 | Anti-GPC3 (M18D4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | M18D4 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3008 | Anti-GPC3 (4A6) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 4A6 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3009 | Anti-GPC3 (4A6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 4A6 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3010 | Anti-GPC3 (M3C11) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | M3C11 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3011 | Anti-GPC3 (M3C11) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | M3C11 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3012 | Anti-GPC3 (GT165) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | GT165 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
| CAR-ZP3013 | Anti-GPC3 (GT165) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | GT165 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
